Alvaro Martinez Mesa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Alvaro Martinez Mesa has a total of 78 co-authors. Here are the top co-authors by number of shared publications:
Eva Cabrera Cesar
Hospital Universitario Virgen de la Victoria, Malaga, Spain
5 shared publicationsNuria Reina Marfil
Hospital Universitario Virgen de la Victoria, Malaga, Spain
4 shared publicationsAna Aguilar Galvez
Hospital Virgen de la Victoria, Málaga, Spain
3 shared publicationsEsther Sanchez Alvarez
Hospital Universitario Virgen de la Victoria, Malaga, Spain
3 shared publications- Alicia Padilla-Galo
Hospital Universitario Virgen de la Victoria, Malaga, Spain
2 shared publications - Ana Gómez-Bastero Fernández
Hospital Universitario Virgen Macarena, Sevilla, Spain
2 shared publications
Latest Publications
- Open Access
- 12 June 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (12) , 4564
Long-Term Adherence to Benralizumab and Sustained Clinical Benefits in Patients with Severe Eosinophilic Asthma: Insights from GALERNA, a Retrospective Real-World Study in Spain
Background: The GALERNA study is a retrospective real-world observational study conducted across 21 hospitals in Spain, aiming to evaluate long-term clinical benefits and adherence to benralizumab in 255 adult patients with severe eosinophilic asthma (SEA) over a follow-up period of up to 144 weeks. Objectives: Primary objectives focused on assessing adherence to benralizumab, while secondary objectives included the description of severe asthma exacerbation rates, systemic corticosteroid (SCS) use, persistence to benralizumab, lung function, asthma control, and the proportion of patients achieving super-response or clinical remission. Data were collected at baseline (48 weeks prior to benralizumab initiation/index date), follow-up 1 (FUP1) (0–48 weeks), FUP2 (49–96 weeks), and FUP3 (97–144 weeks) after the index date. Results: At baseline, patients demonstrated a substantial disease burden characterised by impaired lung function, poorly controlled asthma, and frequent severe exacerbations. The results indicated high adherence rates to benralizumab, with 92.9% of patients receiving each of the prescribed doses of benralizumab at week 48 and 70.6% at week 144. Patients showed substantial and sustained clinical improvements, with a reduction in the proportion of individuals presenting at least one severe exacerbation from baseline to FUP3 and a 74% decrease in SCS use for the same period. Lung function also improved, with the proportion of patients achieving pre-bronchodilator FEV1 ≥ 80% rising to 52% at 144 weeks. Furthermore, mean Asthma Control Test (ACT) scores increased to 20.5, with 68.5% of patients achieving well-controlled asthma (ACT ≥ 20). By the end of the study, 63.6% of patients achieved super-response and 39.1% showed clinical remission, with an overall benralizumab persistence of 79.8% during all follow-up periods. Conclusions: The GALERNA study provides compelling real-world evidence that benralizumab affords marked and sustained clinical benefits together with high long-term adherence in Spanish SEA patients, reinforcing its usefulness as a long-term therapeutic option in routine clinical practice.
- 12 June 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (12) , 4564
Open AccessLong-Term Adherence to Benralizumab and Sustained Clinical Benefits in Patients with Severe Eosinophilic Asthma: Insights from GALERNA, a Retrospective Real-World Study in Spain
Background: The GALERNA study is a retrospective real-world observational study conducted across 21 hospitals in Spain, aiming to evaluate long-term clinical benefits and adherence to benralizumab in 255 adult patients with severe eosinophilic asthma (SEA) over a follow-up period of up to 144 weeks. Objectives: Primary objectives focused on assessing adherence to benralizumab, while secondary objectives included the description of severe asthma exacerbation rates, systemic corticosteroid (SCS) use, persistence to benralizumab, lung function, asthma control, and the proportion of patients achieving super-response or clinical remission. Data were collected at baseline (48 weeks prior to benralizumab initiation/index date), follow-up 1 (FUP1) (0–48 weeks), FUP2 (49–96 weeks), and FUP3 (97–144 weeks) after the index date. Results: At baseline, patients demonstrated a substantial disease burden characterised by impaired lung function, poorly controlled asthma, and frequent severe exacerbations. The results indicated high adherence rates to benralizumab, with 92.9% of patients receiving each of the prescribed doses of benralizumab at week 48 and 70.6% at week 144. Patients showed substantial and sustained clinical improvements, with a reduction in the proportion of individuals presenting at least one severe exacerbation from baseline to FUP3 and a 74% decrease in SCS use for the same period. Lung function also improved, with the proportion of patients achieving pre-bronchodilator FEV1 ≥ 80% rising to 52% at 144 weeks. Furthermore, mean Asthma Control Test (ACT) scores increased to 20.5, with 68.5% of patients achieving well-controlled asthma (ACT ≥ 20). By the end of the study, 63.6% of patients achieved super-response and 39.1% showed clinical remission, with an overall benralizumab persistence of 79.8% during all follow-up periods. Conclusions: The GALERNA study provides compelling real-world evidence that benralizumab affords marked and sustained clinical benefits together with high long-term adherence in Spanish SEA patients, reinforcing its usefulness as a long-term therapeutic option in routine clinical practice.
- Open Access
Rectus Femoris Cross-Sectional Area and Phase Angle asPredictors of 12-Month Mortality in Idiopathic Pulmonary Fibrosis Patients
Background: The value of the phase angle (PhA), measured via bioelectrical impedance analysis (BIA), could be considered a good marker of the cell mass and the cell damage of a patient; however, there are new techniques, such as muscle ultrasonography, that allow the quantity and quality of muscle to be assessed in a minimally invasive way. The aim of this study is to determine the prognostic value of morphofunctional techniques in the prognosis of mortality in patients with idiopathic pulmonary fibrosis (IPF). Methods: This multicenter, cross-sectional study included 86 patients with idiopathic pulmonary fibrosis with a mean age of 71 years, 82.7% of whom were male. The nutritional risk of the patients was assessed by means of questionnaires, such as the Subjective Global Assessment (SGA), and non-invasive functional techniques, including BIA, nutritional ultrasound, and hand grip strength (HGS). Statistical analysis of the sample was performed using JAMOVI version 2.3.22. Results: Correlations were made between the RF-CSA techniques with PhA (r = 0.48, p < 0.001), BCM (r = 0.70, p < 0.001), SMI (r = 0.64, p < 0.001), and HGS (r = 0.54, p < 0.001). The cut-off points for 12-month mortality were PhA = 4.5° (AUC = 0.722, sensitivity of 72.7% and specificity of 66.6%), BCM = 28.8 kg (AUC = 0.609, sensitivity of 32.4% and specificity of 100.0%), RF-CSA = 3.00 cm2 (AUC = 0.857, sensitivity of 64.4% and specificity of 100.0%), 6MMW = 420 m (AUC = 0.830, sensitivity of 63.27% and specificity of 100.0%), and TUG = 7.2 s (AUC = 0.771, sensitivity of 100.0% and specificity of 56.67%). In addition, a multivariate analysis was performed with RF-CSA, HR = 8.11 (1.39–47.16, p = 0.020), and PhA of 6.35 (1.29–31.15, p = 0.023), taking into account age, sex, and BMI to determine mortality. Finally, a Kaplan–Meier survival analysis was conducted with low or normal values for classical parameters (GAP and T6MM) and new parameters (PhA, BCM, RF-CSA, and TUG). Conclusion: RF-CSA and PhA were shown to be good prognostic markers of 12-month mortality and could, therefore, be useful screening tools to complement the nutritional assessment of IPF patients.
Open AccessRectus Femoris Cross-Sectional Area and Phase Angle asPredictors of 12-Month Mortality in Idiopathic Pulmonary Fibrosis Patients
Background: The value of the phase angle (PhA), measured via bioelectrical impedance analysis (BIA), could be considered a good marker of the cell mass and the cell damage of a patient; however, there are new techniques, such as muscle ultrasonography, that allow the quantity and quality of muscle to be assessed in a minimally invasive way. The aim of this study is to determine the prognostic value of morphofunctional techniques in the prognosis of mortality in patients with idiopathic pulmonary fibrosis (IPF). Methods: This multicenter, cross-sectional study included 86 patients with idiopathic pulmonary fibrosis with a mean age of 71 years, 82.7% of whom were male. The nutritional risk of the patients was assessed by means of questionnaires, such as the Subjective Global Assessment (SGA), and non-invasive functional techniques, including BIA, nutritional ultrasound, and hand grip strength (HGS). Statistical analysis of the sample was performed using JAMOVI version 2.3.22. Results: Correlations were made between the RF-CSA techniques with PhA (r = 0.48, p < 0.001), BCM (r = 0.70, p < 0.001), SMI (r = 0.64, p < 0.001), and HGS (r = 0.54, p < 0.001). The cut-off points for 12-month mortality were PhA = 4.5° (AUC = 0.722, sensitivity of 72.7% and specificity of 66.6%), BCM = 28.8 kg (AUC = 0.609, sensitivity of 32.4% and specificity of 100.0%), RF-CSA = 3.00 cm2 (AUC = 0.857, sensitivity of 64.4% and specificity of 100.0%), 6MMW = 420 m (AUC = 0.830, sensitivity of 63.27% and specificity of 100.0%), and TUG = 7.2 s (AUC = 0.771, sensitivity of 100.0% and specificity of 56.67%). In addition, a multivariate analysis was performed with RF-CSA, HR = 8.11 (1.39–47.16, p = 0.020), and PhA of 6.35 (1.29–31.15, p = 0.023), taking into account age, sex, and BMI to determine mortality. Finally, a Kaplan–Meier survival analysis was conducted with low or normal values for classical parameters (GAP and T6MM) and new parameters (PhA, BCM, RF-CSA, and TUG). Conclusion: RF-CSA and PhA were shown to be good prognostic markers of 12-month mortality and could, therefore, be useful screening tools to complement the nutritional assessment of IPF patients.
- 9 September 2023
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 62 (suppl 67) , PA3615
ORBE II study: clinical characteristics and outcomes after treatment with benralizumab according to baseline blood eosinophil count
Background: When prescribing a biologic in severe asthma, it is necessary to understand the impact of baseline patient (pts) characteristics, including eosinophils (eos). Aims and objectives: To describe pts characteristics and one-year clinical outcomes in ORBE II study pts based on initial blood eos count (BEC). Methods: ORBE II (NTC04648839) is a real-world retrospective multicenter study conducted in severe eosinophilic asthma pts treated with benralizumab in Spain. Pts were split into two groups according to their BEC (low eos [<300 eos/µL] and high eos [≥300]). Results: High eos pts had more T2 inflammation (higher FeNO and IgE) and presence of allergic asthma and comorbid nasal polyposis. Low eos pts presented more exacerbations and hospitalizations and a similar % of corticosteroid dependence. An important reduction of severe exacerbations, emergency room visits, and hospitalizations, and an improvement in ACT and lung function was observed in both groups, with a more pronounced effect in high eos pts (Table). Conclusions: These results support the effectiveness of benralizumab in pts regardless of their baseline BEC.
- 9 September 2023
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 62 (suppl 67) , PA3615
ORBE II study: clinical characteristics and outcomes after treatment with benralizumab according to baseline blood eosinophil count
Background: When prescribing a biologic in severe asthma, it is necessary to understand the impact of baseline patient (pts) characteristics, including eosinophils (eos). Aims and objectives: To describe pts characteristics and one-year clinical outcomes in ORBE II study pts based on initial blood eos count (BEC). Methods: ORBE II (NTC04648839) is a real-world retrospective multicenter study conducted in severe eosinophilic asthma pts treated with benralizumab in Spain. Pts were split into two groups according to their BEC (low eos [<300 eos/µL] and high eos [≥300]). Results: High eos pts had more T2 inflammation (higher FeNO and IgE) and presence of allergic asthma and comorbid nasal polyposis. Low eos pts presented more exacerbations and hospitalizations and a similar % of corticosteroid dependence. An important reduction of severe exacerbations, emergency room visits, and hospitalizations, and an improvement in ACT and lung function was observed in both groups, with a more pronounced effect in high eos pts (Table). Conclusions: These results support the effectiveness of benralizumab in pts regardless of their baseline BEC.
- 5 September 2021
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 58 (suppl 65) , PA508
Histology of lung cancer and pulmonary embolism. Are they related?
Lung cancer is the one with the highest mortality in the developed world and one of the tumors with the greatest relationship with the development of pulmonary embolism(PE). We aim to analyze whether the histopathological differences are related to the development of PE. A retrospective study was carried out on a random sample of 148 on which the variables: age, gender, stage, histology and biomarkers. Most of the patients were 114 males(77%) with a mean age of 67.02 years. Of the total of patients, 20 (13.51%) suffered PE during the development of their disease. The prevalence of each histopathological type and the number of PE in each one is expressed in Table1. Thus, the most frequent histopathological type was adenocarcinoma and the most common stage 4 (Figure2). This higher prevalence of PE in adenocarcinoma was statistically significant (p 0.045). PDL1 positive patients had a higher prevalence of PE, however it was not significant (p 0.106). The prevalence of PE in patients with lung cancer is increased, especially in stage IV and adenocarcinoma. Although the prevalence of PE was higher in the PDL1 group, the results were not conclusive and further studies are required.
- 5 September 2021
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 58 (suppl 65) , PA508
Histology of lung cancer and pulmonary embolism. Are they related?
Lung cancer is the one with the highest mortality in the developed world and one of the tumors with the greatest relationship with the development of pulmonary embolism(PE). We aim to analyze whether the histopathological differences are related to the development of PE. A retrospective study was carried out on a random sample of 148 on which the variables: age, gender, stage, histology and biomarkers. Most of the patients were 114 males(77%) with a mean age of 67.02 years. Of the total of patients, 20 (13.51%) suffered PE during the development of their disease. The prevalence of each histopathological type and the number of PE in each one is expressed in Table1. Thus, the most frequent histopathological type was adenocarcinoma and the most common stage 4 (Figure2). This higher prevalence of PE in adenocarcinoma was statistically significant (p 0.045). PDL1 positive patients had a higher prevalence of PE, however it was not significant (p 0.106). The prevalence of PE in patients with lung cancer is increased, especially in stage IV and adenocarcinoma. Although the prevalence of PE was higher in the PDL1 group, the results were not conclusive and further studies are required.
- 5 September 2021
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 58 (suppl 65) , PA3672
Corticotherapy in SARS CoV 2 pneumonia. Is it useful?
In March, the WHO classified the SARS CoV2 disease (COVID19) as a pandemic. Since then, medical teams around the world have been searching for effective treatment. Our goal has been to see the utility of dexamethasone in patients admitted with pneumonia caused by COVID19. A retrospective study was carried out with a sample obtained by systematic sampling of 68 patients, the collected variables are described below. Of the entire sample, 55.88% of the patients were men and 34 were treated with dexamethasone. The variables of age, days of admission, need and days in ICU are shown in Table 1. The only statistically significant was the number of days in ICU p 0.045. Of the patients admitted to the ICU, those treated with dexamethasone did not require invasive mechanical ventilation (only non-invasive). Inflammatory parameters were collected at admission to assess poor prognostic factors that could affect the outcome. They are shown in figure 1 without significant differences found. We conclude that the role of dexamethasone remains uncertain and further studies are needed. However, after evaluating the data, ICU days decreased as well as the need for IMV.
- 5 September 2021
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 58 (suppl 65) , PA3672
Corticotherapy in SARS CoV 2 pneumonia. Is it useful?
In March, the WHO classified the SARS CoV2 disease (COVID19) as a pandemic. Since then, medical teams around the world have been searching for effective treatment. Our goal has been to see the utility of dexamethasone in patients admitted with pneumonia caused by COVID19. A retrospective study was carried out with a sample obtained by systematic sampling of 68 patients, the collected variables are described below. Of the entire sample, 55.88% of the patients were men and 34 were treated with dexamethasone. The variables of age, days of admission, need and days in ICU are shown in Table 1. The only statistically significant was the number of days in ICU p 0.045. Of the patients admitted to the ICU, those treated with dexamethasone did not require invasive mechanical ventilation (only non-invasive). Inflammatory parameters were collected at admission to assess poor prognostic factors that could affect the outcome. They are shown in figure 1 without significant differences found. We conclude that the role of dexamethasone remains uncertain and further studies are needed. However, after evaluating the data, ICU days decreased as well as the need for IMV.
- 7 September 2020
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 56 (suppl 64)
Evolution in the pathological study of lung cancer
Introduction: The emergence of drugs against specific molecular biomarkers in lung cancer has led to the need for a more accurate diagnosis through obtaining better quality cytohistological samples. The objective of the study has been evaluated the pathological samples used for diagnosis of lung cancer and its histological type. Methods: A descriptive study of a random sample of 373 patients who were diagnosed with lung cancer in our hospital was performed. Demographic, clinical and pathological variables were recognized. Results: 77.21% (288) were male, with an average age of 66.74 years. 75.34% (288) were diagnosed by biopsy, obtained in 71.1% (200 samples) by pulmonologists (endobronchial or ultrasound-guided BAG). The most frequent cytological and histological diagnosis was non-small cell lung carcinoma and adenocarcinoma respectively. Conclusions: The shift to higher pathology samples is related to the increase in the therapeutic arsenal against lung cancer and a more personalized medicine.
- 7 September 2020
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 56 (suppl 64)
Evolution in the pathological study of lung cancer
Introduction: The emergence of drugs against specific molecular biomarkers in lung cancer has led to the need for a more accurate diagnosis through obtaining better quality cytohistological samples. The objective of the study has been evaluated the pathological samples used for diagnosis of lung cancer and its histological type. Methods: A descriptive study of a random sample of 373 patients who were diagnosed with lung cancer in our hospital was performed. Demographic, clinical and pathological variables were recognized. Results: 77.21% (288) were male, with an average age of 66.74 years. 75.34% (288) were diagnosed by biopsy, obtained in 71.1% (200 samples) by pulmonologists (endobronchial or ultrasound-guided BAG). The most frequent cytological and histological diagnosis was non-small cell lung carcinoma and adenocarcinoma respectively. Conclusions: The shift to higher pathology samples is related to the increase in the therapeutic arsenal against lung cancer and a more personalized medicine.
- 7 September 2020
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 56 (suppl 64)
Towards personalized treatment in non-small-cell lung carcinoma
Introduction: Personalized medicine is key to deciding the optimal treatment for a patient with lung cancer. In recent years, biomolecular markers have been discovered that have allowed increasing the therapeutic against lung cancer, especially in advanced stages. Our objective has been to evaluate their prevalence in our environment. Methods: A retrospective study has been conducted with a random selection of 374 patients. Age, gender, year of diagnosis, pathological diagnosis and biomarkers (EGFR, ALK and PDL-1) were recorded. Results: 374 cases have been analysed. The average age was 66.74 years and 77.21% were male. 78.28% (292) were non-small-cell lung carcinoma (NSCLC) of which 59.58% (174) had a study of markers being 35.05 positive (61). Figure 1 shows the annual evolution according to the number of requested and positive studies obtained. The individual distribution of each of the markers can be seen in table 1 Conclusion: These data show the increasing importance of these biomolecular markers due to their therapeutic implications.
- 7 September 2020
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 56 (suppl 64)
Towards personalized treatment in non-small-cell lung carcinoma
Introduction: Personalized medicine is key to deciding the optimal treatment for a patient with lung cancer. In recent years, biomolecular markers have been discovered that have allowed increasing the therapeutic against lung cancer, especially in advanced stages. Our objective has been to evaluate their prevalence in our environment. Methods: A retrospective study has been conducted with a random selection of 374 patients. Age, gender, year of diagnosis, pathological diagnosis and biomarkers (EGFR, ALK and PDL-1) were recorded. Results: 374 cases have been analysed. The average age was 66.74 years and 77.21% were male. 78.28% (292) were non-small-cell lung carcinoma (NSCLC) of which 59.58% (174) had a study of markers being 35.05 positive (61). Figure 1 shows the annual evolution according to the number of requested and positive studies obtained. The individual distribution of each of the markers can be seen in table 1 Conclusion: These data show the increasing importance of these biomolecular markers due to their therapeutic implications.
- 7 September 2020
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 56 (suppl 64)
Evolution of patients with severe asthma treated with mepolizumab
Introduction: Severe asthma means asthma that is uncontrolled despite adherence with maximal optimized therapy and treatment of contributory factors, or that worsens when high dose treatment is decreased. Mepolizumab arises as an asthma treatment in step 5 of GINA. The objective of the study was to assess the evolution of the levels of eosinophils, FeNO and FEV1 after the start of Mepolizumab. Methods: It is a prospective study of patients who have started treatment with mepolizumab in our asthma office. We collected different variables before and after the start of mepolizumab. Results: 19 patients have been collected, of which 78.9% (15) were women, with an average age of 51.9 years and an average IgE level of 85.84. Conclusions: -The use of mepolizumab improves lung function and FENO levels with a reduction in the number of eosinophils, with the consequent subjective clinical improvement. -Given the data, it is expected that in the annual control the tendency to improve these patients will be confirmed
- 7 September 2020
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 56 (suppl 64)
Evolution of patients with severe asthma treated with mepolizumab
Introduction: Severe asthma means asthma that is uncontrolled despite adherence with maximal optimized therapy and treatment of contributory factors, or that worsens when high dose treatment is decreased. Mepolizumab arises as an asthma treatment in step 5 of GINA. The objective of the study was to assess the evolution of the levels of eosinophils, FeNO and FEV1 after the start of Mepolizumab. Methods: It is a prospective study of patients who have started treatment with mepolizumab in our asthma office. We collected different variables before and after the start of mepolizumab. Results: 19 patients have been collected, of which 78.9% (15) were women, with an average age of 51.9 years and an average IgE level of 85.84. Conclusions: -The use of mepolizumab improves lung function and FENO levels with a reduction in the number of eosinophils, with the consequent subjective clinical improvement. -Given the data, it is expected that in the annual control the tendency to improve these patients will be confirmed